title: Effects of hydroxysafflor yellow A in the attenuation of MPTP neurotoxicity in mice.
abstract: Parkinson's disease (PD) is a progressive neurodegenerative disorder whose etiology is not understood. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse model is widely used for studying PD. The present study was undertaken to investigate the effect of hydroxysafflor yellow A (HSYA) on MPTP-induced neurotoxicity in mice. Pretreatment with HSYA at a dose of 2, 8 mg/kg for a week was followed by intraperitoneal injection with MPTP (30 mg/kg) for five consecutive days. Next, the subsequent behavior, biochemical index and immunohistochemical manifestations in mice were determined. Behavioral testing showed that MPTP-treated mice exhibited motor deficits but HSYA at dose of 8 mg/kg prevented the appearance of motor abnormalities. Treatment with HSYA at dose of 8 mg/kg attenuated the reduction of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in striatum. It also showed that the activity of SOD, catalase activity and GSH levels were significantly higher, while the levels of malondialdehyde (MDA) and hydroxyl radicals was lower, in the HSYA-treated mice compared to the MPTP-treated mice. The MPTP-treated mice exhibited the loss of tyrosine hydroxylase-containing dopaminergic neurons in substantia nigra. However, HSYA-treated mice showed a protective effect. Our results indicated that HSYA possesses neuroprotective effects and is a promising anti-Parkinson's disease drug which is worthy of further study.
authors.affiliation: Department of Physiology, School of Basic Medical Sciences, Jilin University, No. 2 Xinmin Street, Changchun 130021, China.
authors.forename: B
authors.initials: B
authors.lastname: Han
authors.forename: H
authors.initials: H
authors.lastname: Zhao
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D002374:Catalase / Q000378:metabolism; D002599:Chalcone / Q000031:analogs & derivatives* / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D005978:Glutathione / Q000378:metabolism; D006719:Homovanillic Acid / Q000378:metabolism; D007150:Immunohistochemistry; D020267:MPTP Poisoning / Q000517:prevention & control*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D011809:Quinones / Q000494:pharmacology*; D013482:Superoxide Dismutase / Q000378:metabolism
chemical_list: D011809:Quinones; D015102:3,4-Dihydroxyphenylacetic Acid; C085278:hydroxysafflor yellow A; D008315:Malondialdehyde; D002599:Chalcone; D002374:Catalase; D013482:Superoxide Dismutase; D005978:Glutathione; D004298:Dopamine; D006719:Homovanillic Acid
references.citation: Invest Ophthalmol Vis Sci. 1993 Jan;34(1):72-80
references.pmid: 8425843
references.citation: Brain Res. 2000 Jan 3;852(1):221-4
references.pmid: 10661517
references.citation: Eur J Pharm Sci. 2001 Jan;12(3):231-8
references.pmid: 11113642
references.citation: Neurosci Lett. 2005 Sep 23;386(1):58-62
references.pmid: 16002219
references.citation: Chem Res Toxicol. 2008 Jan;21(1):172-88
references.pmid: 18052107
references.citation: Anal Biochem. 1979 Jun;95(2):351-8
references.pmid: 36810
references.citation: Brain Res. 1987 Feb 3;402(2):269-74
references.pmid: 3493826
references.citation: Brain Res. 2002 Aug 30;947(2):271-83
references.pmid: 12176170
references.citation: Exp Neurol. 2004 Feb;185(2):281-9
references.pmid: 14736509
references.citation: Brain Res. 1990 Oct 1;528(2):181-8
references.pmid: 2271921
references.citation: Neurochem Res. 2002 Jun;27(6):457-64
references.pmid: 12199149
references.citation: Methods Enzymol. 1984;105:121-6
references.pmid: 6727660
references.citation: J Biol Chem. 1951 Nov;193(1):265-75
references.pmid: 14907713
references.citation: Mol Neurobiol. 1998 Jun;16(3):285-309
references.pmid: 9626667
references.citation: J Neurochem. 1993 Oct;61(4):1191-206
references.pmid: 8376979
references.citation: J Biol Chem. 1969 Nov 25;244(22):6049-55
references.pmid: 5389100
references.citation: Behav Genet. 2000 May;30(3):171-82
references.pmid: 11105391
references.citation: FASEB J. 1998 Jul;12(10):905-12
references.pmid: 9657530
references.citation: Adv Neurol. 1987;45:19-34
references.pmid: 2881444
references.citation: Pharmacology. 2008;82(2):121-6
references.pmid: 18583922
references.citation: Science. 1983 Feb 25;219(4587):979-80
references.pmid: 6823561
references.citation: Anal Biochem. 1966 Mar;14(3):434-40
references.pmid: 5944947
references.citation: Mov Disord. 1998;13 Suppl 1:35-8
references.pmid: 9613716
references.citation: Neurochem Res. 2008 Jun;33(6):980-4
references.pmid: 17768676
references.citation: J Neural Transm (Vienna). 2001;108(11):1263-82
references.pmid: 11768626